Sydney Pharmacy School, The University of Sydney, Camperdown, Australia.
Key Laboratory of Nuclear Medicine, Ministry of Health, Jiangsu Key Laboratory of Molecular Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, Wuxi, Jiangsu, China.
Planta Med. 2021 Jun;87(7):511-527. doi: 10.1055/a-1377-2596. Epub 2021 Mar 24.
Retinal diseases are a leading cause of impaired vision and blindness but some lack effective treatments. New therapies are required urgently to better manage retinal diseases. Natural pentacyclic triterpenoids and their derivatives have a wide range of activities, including antioxidative, anti-inflammatory, cytoprotective, neuroprotective, and antiangiogenic properties. Pentacyclic triterpenoids have great potential in preventing and/or treating retinal pathologies. The pharmacological effects of pentacyclic triterpenoids are often mediated through the modulation of signalling pathways, including nuclear factor erythroid-2 related factor 2, high-mobility group box protein 1, 11-hydroxysteroid dehydrogenase type 1, and Src homology region 2 domain-containing phosphatase-1. This review summarizes recent and evidence for the pharmacological potential of pentacyclic triterpenoids in the prevention and treatment of retinal diseases. The present literature supports the further development of pentacyclic triterpenoids. Future research should now attempt to improve the efficacy and pharmacokinetic behaviour of the agents, possibly by the use of medicinal chemistry and targeted drug delivery strategies.
视网膜疾病是导致视力障碍和失明的主要原因，但有些疾病缺乏有效的治疗方法。迫切需要新的疗法来更好地治疗视网膜疾病。天然五环三萜及其衍生物具有广泛的活性，包括抗氧化、抗炎、细胞保护、神经保护和抗血管生成特性。五环三萜类化合物在预防和/或治疗视网膜病变方面具有巨大的潜力。五环三萜类化合物的药理作用通常通过调节信号通路来介导，包括核因子红细胞 2 相关因子 2、高迁移率族蛋白 1、11-β-羟类固醇脱氢酶 1 和Src 同源区 2 结构域磷酸酶 1。本文综述了近年来五环三萜类化合物在预防和治疗视网膜疾病方面的药理作用的最新证据。目前的文献支持进一步开发五环三萜类化合物。未来的研究现在应该试图通过使用药物化学和靶向药物传递策略来提高药物的疗效和药代动力学行为。
